eligibility_summary
Eligible: pediatric (1–18) and adult patients receiving CAR‑T for refractory acute leukemia or B‑cell lymphoma who are CMV‑seropositive. Retrospective: written non‑opposition (minors: both parents + child if appropriate, or child + legal representative if only one parent alive), signed by investigator. Prospective: written consent signed by patient and investigator (minors: both parents or legal representative). Exclude: CMV‑seronegative, no social security, guardianship/curatorship, AME.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Observational cohort study evaluating incidence and risk factors of CMV reactivation within 3 months after CAR-T cell therapy in CMV-seropositive patients with refractory acute leukemia or B-cell lymphoma. No study drug is given. Contextual antivirals: letermovir (small-molecule CMV prophylactic, inhibits CMV DNA terminase complex/viral DNA processing), ganciclovir (nucleoside analog inhibiting viral DNA polymerase), and foscarnet (pyrophosphate analog inhibiting viral DNA polymerase). Targets/pathways: CAR-T cells directed against malignant hematologic cells (antigen not specified), investigation centers on CMV reactivation and immune dysregulation, including reactivation of persistent viruses (TTV, redondovirus, pegivirus) that reflect impaired antiviral immunity and may impact antitumor immunosurveillance.